InvestorsHub Logo
Followers 72
Posts 4827
Boards Moderated 0
Alias Born 01/24/2004

Re: cjgaddy post# 58520

Friday, 11/18/2011 3:44:06 PM

Friday, November 18, 2011 3:44:06 PM

Post# of 345605
One of the two AntiPS posters that was presented on 11-16-11 at the DTRA 2011 CBD S&T Conf. in Vegas, #W15-048 by Peregrine’s Dr. Cyril Empig, was posted (PDF) to PeregrineInc.com today (FEATURES tab): “Phosphatidylserine as a Therapeutic Target for the Treatment of Francisella Tularensis & Yersinia Pestis Infections” – see below. Interesting, the senior author of #W15-048 is Rachel E. Dean of Biomedical Sciences/DSTL Porton Down/UK, “one of the most sensitive & secret experimental sites in the UK.” – again, see below…

Nov14-18 2011: DTRA’s 2011 CBD S&T Conference (LasVegas)
http://cbdstconf2011.sainc.com
“The Defense Threat Reduction Agency (DTRA), executing the Joint Science and Technology Office (JSTO) function within the Chemical & Biological Defense Program (CBDP), invites you to join us at the 2011 Chemical & Biological Defense Science and Technology (CBD S&T) Conference.”
Wednesday Poster Sessions (11-16-2011), track: Therapeutics
http://cbdstconf2011.sainc.com/conference_agenda/WednesdayPosterSession.aspx
. . .I. W15-026 “Phosphatidylserine Targeting Antibodies as Potential Therapeutic Agents for Argentine Hemorrhagic Fever”
Ashley Grant, Univ. of Texas Medical Branch
==> II. W15-048 “Phosphatidylserine as a Therapeutic Target for the Treatment of Francisella Tularensis & Yersinia Pestis Infections”
Cyril Empig*, Peregrine Pharmaceuticals, Inc.
NOTE: *Dr. Cyril Empig was co-author with Dr. Thorpe etal on this 8-2011 presentation by Dr. Thorpe at the Aug 2011 “Intl. Meeting on Cell Biology of Pathogens” in SaoPaulo, Brazil – see http://tinyurl.com/3pjghjz .
- - - - - - -
Dr. Empig’s Poster #W15-048 PDF Posted to PeregrineInc.com 11-18-11:
“Phosphatidylserine as a Therapeutic Target for the Treatment of Francisella Tularensis & Yersinia Pestis Infections”
http://www.peregrineinc.com/images/stories/pdfs/cbdst_bacteria_bavituximab.pdf
Auhor List:
Claire Lonsdale 1, Graeme C. Clark 1, Caroline Rowland 1, Roman Lukaszewski 1, Steven W. King 2, Cyril J. Empig 2, Philip E. Thorpe 3, Rachel E. Dean 1
1 Biomedical Sciences, DSTL Porton Down, Salisbury, Wiltshire, UK
2 Peregrine Pharmaceuticals Inc., 14272 Franklin Ave, Tustin, CA
3 Dept of Pharmacology, Univ. of Texas SW MC, Dallas, TX
- - - - - -
ACKNOWLEDGMENTS:
This research was funded by the Ministry of Defense in the UK. Published with permission of the Defense Science & Technology Laboratory (DSTL) on behalf of the Controller of HMSO. We would like to thank Connie Chang and her team at Peregrine Pharmaceuticals, Inc. (PPHM) for providing the PS-targeting antibody, mch1N11 and isotype control. [Note: AT004 is Fully-Human BAVI=PGN635=1N11]
INTERESTING:
?http://www.dark-places.org.uk/site/dstl-porton-down
DSTL (Defense Science & Technology Laboratory) Porton Down is one of the most sensitive & secret experimental sites in the UK. The site is based around a technology park conducting scientific & military research, including forensic DNA and a technology transfer initiative - Ploughshare Innovations. Historically, it is also the site which has been linked to many infamous incidents relating to biochemical warfare experiments, also conducted off-site and including spraying public places - Salisbury & Weymouth, for example. Site is adjacent to MOD Boscombe Down and the entire area is wrapped by a large area of land which is declared as a Danger Zone. . . In 1995, the Establishment became part of the Defense Evaluation & Research Agency (DERA), an executive agency of MOD evolved in 1994 from proposals of the "Front Line First" Defense Cost Studies. In 2001, DERA split into 2 organisations: QinetiQ, a private company, and DSTL (Defense Science & Technology Laboratory), which remains an agency of MOD. Porton Down is now known as DSTL Porton Down.”

http://www.peregrineinc.com/images/stories/pdfs/cbdst_bacteria_bavituximab.pdf











*end*
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News